In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.
Manual assessments of prostate specific membrane antigen (PSMA) scoring and measures such as standardized uptake value (SUV) mean and maximum SUV (SUVmax) on positron emission tomography (PET) scans can be tedious and are not always accurate, noted Hong Song, M.D., Ph.D., in a recent interview.
With this in mind, Dr. Song and colleagues recently evaluated the combination of aPROMISE software (PYLARIFY AI, Exini Diagnostics AB/Lantheus Holdings), an FDA-cleared deep learning platform for quantitative assessment of PSMA PET/CT images, and piflufostat F 18 (PYLARIFY®, Lantheus Holdings) to assess 69 patients with prostate cancer recurrence and the impact of quantitative measures upon subsequent biochemical progression-free survival.
In some of the findings from the study, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, the researchers noted that higher PSMA-avid total tumor volume (PSMAAttv) and a higher aPSMA score for bone metastases were both associated with shorter biochemical progression-free survival in patients with prostate cancer.
(Editor’s note: For related content, see “Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?,” “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer” and “Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence After a Prostatectomy?”)
“There are quantitative tools now that are readily available to help us have this prognostic evaluation of (patients) who may be at high risk for subsequent progression (of prostate cancer and) should be followed more closely. … There is more information than meets the eye in the scan that we can now quantify and extract,” emphasized Dr. Song, an assistant professor of radiology (nuclear medicine) at Stanford University.
For more insights from Dr. Song, watch the video below.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.